欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (6): 679-683.

• 定量药理学 • 上一篇    下一篇

泛昔洛韦缓释胶囊的人体药代动力学研究及其特征分析

胡海棠1, 谭志刚1, 王晓丹2, 郑家润2, 崔盘根2, 陈正琴2, 陈沄2   

  1. 1丽珠集团医学临床研究中心, 珠海 519020, 广东;
    2中国医学科学院皮肤病研究所, 南京 210042, 江苏
  • 收稿日期:2008-03-25 修回日期:2008-06-18 发布日期:2020-10-14
  • 通讯作者: 陈沄,女,副研究员,硕士生导师,研究方向:药代动力学和皮肤病药物治疗学。Tel:025-85471967 E-mail:iddrd@jlonline.com
  • 作者简介:胡海棠,男,医学硕士,研究方向:临床药理。Tel:0756-8135888 E-mail:huhaitang@livzon.com.cn

Pharmacokinetics profile of famciclovir sustained release capsules in healthy volunteers

HU Hai-tang1, TAN Zhi-guang1, WANG Xiao-dan2, ZHENG Jia-run2, XU Lan-fang2, CHUI Pangen2, CHEN Zhen-qing2, CHEN Yun2   

  1. 1Clinical Research Center, Livzon Pharmaceutical Group Inc., Zhuhai 519020, Guangdong, China;
    2Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, 210042, Jiangsu, China
  • Received:2008-03-25 Revised:2008-06-18 Published:2020-10-14

摘要: 目的: 研究泛昔洛韦缓释胶囊的人体药代动力学行为,证明受试制剂的缓释特征,评价其与参比制剂泛昔洛韦片的相对生物利用度。方法: 单次给药试验四阶拉丁方试验设计,受试制剂250、375、750mg三剂量组及参比制剂750mg组;多次给药试验两周期随机交叉试验设计。HPLC法测定血药浓度,3P97软件进行数据处理及药代动力学分析。结果: 12例受试者单次口服泛昔洛韦缓释胶囊250、375、750mg后,Cmax分别为(0.31±0.06)、(0.51±0.09)、(1.0±0.16) μg/mL,tmax分别为(4.4±1.8)、(4.0±1.4)、(4.3±1.8)h,平均滞留时间(MRT)分别为(6.9±1.3)、(7.3±1.0)、(7.6±0.7)h,AUC0-24分别为(3.3±0.8)、(5.2±1.1)、(11.3±1.4)μg·mL-1·h;普通片750mg给药后,Cmax为(3.81±0.38) μg/mL,tmax为(1.2±0.6)h,MRT为(3.3±0.4)h,AUC0-24为(13.7±1.5)μg·mL-1·h。缓释胶囊单次给药后的相对生物利用度为(81.96±2.54)%,两种制剂的生物利用度相当。10例受试者每日口服750mg泛昔洛韦缓释胶囊和普通片3d后缓释胶囊和普通片血药浓度均已达稳态,Cmin分别为(0.32±0.13)、(0.16±0.04) μg/mL。达稳态后的Cmax分别为(0.71±0.14)、(1.67±0.44) μg/mL,Cav分别为(0.44±0.09)、(0.56±0.13) μg/mL,波动度DF分别为(90±26)%、(270±59)%。缓释胶囊谷浓度明显高于普通片,波动度则明显小于普通片。结论: 泛昔洛韦缓释胶囊具有明显缓释特征,并与普通片生物利用度相当。

关键词: 泛昔洛韦, 缓释胶囊, 药代动力学, 高效液相色谱法, 相对生物利用度

Abstract: AIM: To investigate the pharmacokinetic profile and relative bioavailability of Famciclovir sustained release capsules in healthy volunteers.METHODS: 12 healthy volunteers were divided into four group with single oral dose test famciclovir sustained release capsules(250, 375, 750mg) and conventional Facmciclovir tablets (750 mg) according to an open randomized four way crossover design.A multidose test were given to 10 healthy volunteers according to an open randomized two way crossover design.The concentration of penciclovir in plasma after administration were determinded by HPLC.Pharmacokinetic parameters were calculated with 3P97 program.RESULTS: Concentration-time curves of penciclovir fitted to one-compartment mode, Cmax were (0.31±0.06), (0.51±0.09), (1.0±0.16) μg/mL, tmax (4.4± 1.8), (4.0±1.4), (4.3±1.8) h, MRT (6.9± 1.3), (7.3±1.0), (7.6±0.7) h, AUC0-24 (3.3± 0.8), (5.2±1.1), (11.3±1.4) μg·mL-1·h respectively for famciclovir sustained release capsules;Cmax were (3.81±0.38) μg/mL, tmax (1.2±0.6) h, MRT (3.3±0.4) h, AUC0-24 (13.7±1.5) μg·mL-1·h for conventional tablet.The relative bioavailability was 81.96%±2.54%.The parameters after multi-doses of the sustain released capsules and conventional tablets were as follows: Cmin (0.32±0.13) and (0.16± 0.04) μg/mL, Cmax (0.71±0.14) and 1.67±0.44 μg/mL, Cav (0.44± 0.09) and (0.56± 0.13) μg/mL, DF 90%±26% and 270%±59%, respectively.CONCLUSION: The sustain released capsules have the obvious sustained release characteristic.The two formulation of Famciclovir are of bioequivalence.

Key words: Famciclovir sustained released capsules, pharmacokinetics, relative bioavailability, HPLC

中图分类号: